Singh R - Search Results

1

Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective.

Singh AK, Majumdar S, Singh R, Misra A. Singh AK, et al. Among authors: singh r. Diabetes Metab Syndr. 2020 Sep-Oct;14(5):971-978. doi: 10.1016/j.dsx.2020.06.054. Epub 2020 Jun 27. Diabetes Metab Syndr. 2020. PMID: 32610262 Free PMC article.

2

Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.

Singh AK, Singh R. Singh AK, et al. Among authors: singh r. Expert Rev Clin Pharmacol. 2016;9(2):229-40. doi: 10.1586/17512433.2016.1123616. Epub 2015 Dec 25. Expert Rev Clin Pharmacol. 2016. PMID: 26589238 Review.

3

Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences.

Singh AK, Singh R. Singh AK, et al. Among authors: singh r. Expert Rev Clin Pharmacol. 2016;9(3):409-18. doi: 10.1586/17512433.2016.1131121. Epub 2016 Jan 5. Expert Rev Clin Pharmacol. 2016. PMID: 26732230 Review.

4

Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review.

Singh AK, Singh R. Singh AK, et al. Among authors: singh r. Indian J Endocrinol Metab. 2016 Jan-Feb;20(1):32-42. doi: 10.4103/2230-8210.172278. Indian J Endocrinol Metab. 2016. PMID: 26904466 Free PMC article. Review.

5

Is gliclazide a sulfonylurea with difference? A review in 2016.

Singh AK, Singh R. Singh AK, et al. Among authors: singh r. Expert Rev Clin Pharmacol. 2016 Jun;9(6):839-51. doi: 10.1586/17512433.2016.1159512. Epub 2016 Mar 15. Expert Rev Clin Pharmacol. 2016. PMID: 26924475 Review.

6

SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.

Singh AK, Singh R. Singh AK, et al. Among authors: singh r. Expert Rev Clin Pharmacol. 2017 Apr;10(4):429-442. doi: 10.1080/17512433.2017.1287562. Epub 2017 Feb 6. Expert Rev Clin Pharmacol. 2017. PMID: 28121469 Review.

7

Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.

Singh AK, Singh R. Singh AK, et al. Among authors: singh r. Expert Rev Clin Pharmacol. 2017 Jun;10(6):633-647. doi: 10.1080/17512433.2017.1318061. Epub 2017 Apr 17. Expert Rev Clin Pharmacol. 2017. PMID: 28393583 Review.

8

Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies.

Singh AK, Singh R. Singh AK, et al. Among authors: singh r. Expert Rev Clin Pharmacol. 2019 Apr;12(4):299-308. doi: 10.1080/17512433.2019.1588110. Epub 2019 Mar 11. Expert Rev Clin Pharmacol. 2019. PMID: 30817235

9

Heart Failure Hospitalization with DPP-4 Inhibitors: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Singh AK, Singh R. Singh AK, et al. Among authors: singh r. Indian J Endocrinol Metab. 2019 Jan-Feb;23(1):128-133. doi: 10.4103/ijem.IJEM_613_18. Indian J Endocrinol Metab. 2019. PMID: 31016167 Free PMC article.

10

SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins.

Singh AK, Singh R. Singh AK, et al. Among authors: singh r. Indian J Endocrinol Metab. 2019 Mar-Apr;23(2):175-183. doi: 10.4103/ijem.IJEM_12_19. Indian J Endocrinol Metab. 2019. PMID: 31161099 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results